Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Danapha Pharmaceutical JSCHSTC:DAN 31 Debt-to-Equity is 0.00 as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 815 Drug Manufacturers companies, Danapha Pharmaceutical JSC ranks worse than 122699.26% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Danapha Pharmaceutical JSC's Debt-to-Equity or its related term are showing as below:
HSTC:DAN's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Danapha Pharmaceutical JSC Debt-to-Equity Related Terms
Danapha Pharmaceutical JSC Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danapha Pharmaceutical JSC Debt-to-Equity Chart
Danapha Pharmaceutical JSC Annual Data
Trend
Debt-to-Equity
Danapha Pharmaceutical JSC Semi-Annual Data
Debt-to-Equity
HSTC:DAN vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Danapha Pharmaceutical JSC's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danapha Pharmaceutical JSC Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Danapha Pharmaceutical JSC's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Danapha Pharmaceutical JSC's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danapha Pharmaceutical JSC (HSTC:DAN) has a Debt-to-Equity of 0.00 as of . 20. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Danapha Pharmaceutical JSC and its competitors. According to the industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 815 companies in the Drug Manufacturers industry.
Is Danapha Pharmaceutical JSC's Debt-to-Equity too high?
Danapha Pharmaceutical JSC's current Debt-to-Equity is 0.00. Based on the distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 815 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Danapha Pharmaceutical JSC ranks #999999 out of 815 companies for Debt-to-Equity. This places Danapha Pharmaceutical JSC in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Danapha Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danapha Pharmaceutical JSC's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Danapha Pharmaceutical JSC's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current Debt-to-Equity is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
31GF Score
Get the complete analysis for HSTC:DAN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DAN has been successfully added to your 
